Pharming Group N.V. Files 6-K with Press Release
Ticker: PHAR · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, press-release
TL;DR
Pharming Group N.V. dropped a 6-K with a press release today, check for updates.
AI Summary
Pharming Group N.V. filed a Form 6-K on October 10, 2024, to furnish a press release dated the same day as Exhibit 99.1. The filing does not contain specific financial figures or operational updates within the provided text, but indicates the release of new information by the company.
Why It Matters
This filing signals that Pharming Group N.V. is releasing new information to the public, which could impact its stock price and investor decisions.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of a press release and does not contain inherently risky information.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- October 10, 2024 (date) — Filing and Press Release Date
- 001-39822 (other) — SEC File Number
- Exhibit 99.1 (other) — Attached Document
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to furnish a press release, dated October 10, 2024, as Exhibit 99.1.
What is the SEC file number for Pharming Group N.V.?
The SEC file number for Pharming Group N.V. is 001-39822.
On what date was the press release furnished with this filing?
The press release was furnished on October 10, 2024.
Does Pharming Group N.V. file annual reports under Form 20-F or 40-F?
Pharming Group N.V. files annual reports under Form 20-F, as indicated by the checkmark next to it.
What is the principal executive office address for Pharming Group N.V.?
The principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.
Filing Stats: 1,520 words · 6 min read · ~5 pages · Grade level 13.7 · Accepted 2024-10-10 06:06:04
Filing Documents
- pharminggroupannouncesstrt.htm (6-K) — 34KB
- logo_greyxoriginalxa.jpg (GRAPHIC) — 112KB
- logo_pharmingxoriginala.jpg (GRAPHIC) — 18KB
- 0001828316-24-000033.txt ( ) — 202KB
Forward-Looking Statements
Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred t